Valuation: Iovance Biotherapeutics, Inc.

Capitalization 1.63B 1.56B 1.47B 1.3B 2.31B 141B 2.58B 17.53B 6.5B 58.76B 6.1B 5.98B 249B P/E ratio 2024 *
-4.23x
P/E ratio 2025 * -5.99x
Enterprise value 1.38B 1.33B 1.25B 1.1B 1.97B 120B 2.2B 14.91B 5.53B 49.98B 5.19B 5.09B 212B EV / Sales 2024 *
8.52x
EV / Sales 2025 * 3.36x
Free-Float
90.74%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.46%
1 week-1.05%
Current month-3.76%
1 month-4.41%
3 months-34.46%
6 months-44.31%
Current year-23.92%
More quotes
1 week
5.05
Extreme 5.05
5.78
1 month
5.05
Extreme 5.05
6.50
Current year
5.05
Extreme 5.05
8.15
1 year
5.05
Extreme 5.05
18.33
3 years
3.21
Extreme 3.21
18.73
5 years
3.21
Extreme 3.21
54.21
10 years
3.21
Extreme 3.21
54.21
More quotes
Director TitleAgeSince
Chief Executive Officer 51 2021-06-17
Director of Finance/CFO 52 2020-12-13
Chief Tech/Sci/R&D Officer - 2021-06-30
Manager TitleAgeSince
Director/Board Member 55 2015-02-15
Director/Board Member 57 2016-06-06
Chairman 66 2016-08-15
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+3.46%-1.05%-41.05%-66.35% 1.63B
+0.16%-5.11%-18.19%-35.15% 9.36B
+3.88%-1.24%+60.77%+39.66% 3.07B
-0.60%+9.91%+13.38%-41.03% 2.67B
+0.74%+11.31%+200.90%-40.56% 1.33B
-0.06%+7.72%+114.34%-42.43% 1.26B
+1.10%-5.75%-10.53%-56.12% 731M
+1.58%-9.06%-19.13%-86.05% 584M
+3.91%+7.13%+124.28%+193.19% 276M
+0.32%-3.52%+1.61% - 211M
Average +1.44%-2.61%+42.64%-14.98% 2.11B
Weighted average by Cap. +1.00%-4.29%+19.53%-27.28%
See all sector performances

Financials

2024 *2025 *
Net sales 163M 156M 147M 130M 231M 14.09B 258M 1.75B 649M 5.87B 609M 597M 24.85B 455M 436M 412M 363M 647M 39.45B 722M 4.9B 1.82B 16.43B 1.71B 1.67B 69.58B
Net income -362M -347M -328M -289M -515M -31.42B -575M -3.9B -1.45B -13.08B -1.36B -1.33B -55.42B -260M -249M -235M -207M -370M -22.55B -413M -2.8B -1.04B -9.39B -975M -955M -39.77B
Net Debt -243M -233M -220M -194M -345M -21.07B -386M -2.62B -971M -8.77B -911M -893M -37.16B -100M -96.14M -90.81M -80.08M -143M -8.71B -159M -1.08B -401M -3.62B -376M -369M -15.36B
More financial data * Estimated data
Logo Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Employees
557
More about the company
Date Price Change Volume
25-02-14 5.525 $ +3.46% 6,042,132
25-02-13 5.340 $ 0.00% 7,753,648
25-02-12 5.340 $ +0.95% 5,625,417
25-02-11 5.290 $ -0.56% 9,467,979
25-02-10 5.320 $ -6.50% 11,176,645

Delayed Quote Nasdaq, February 14, 2025 at 11:39 am EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
CCC
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
5.340USD
Average target price
22.96USD
Spread / Average Target
+329.93%
Consensus

Quarterly revenue - Rate of surprise